554 related articles for article (PubMed ID: 25855053)
21. Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort.
Tang H; Liu Y; Wang X; Guan L; Chen W; Jiang H; Lu Y
Medicine (Baltimore); 2018 May; 97(21):e10881. PubMed ID: 29794794
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
[TBL] [Abstract][Full Text] [Related]
23. Impact of guideline adherence on patient outcomes in early-stage epithelial ovarian cancer.
Lee JY; Kim TH; Suh DH; Kim JW; Kim HS; Chung HH; Park NH; Song YS; Kang SB
Eur J Surg Oncol; 2015 Apr; 41(4):585-91. PubMed ID: 25624160
[TBL] [Abstract][Full Text] [Related]
24. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
25. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
[TBL] [Abstract][Full Text] [Related]
26. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
[TBL] [Abstract][Full Text] [Related]
27. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
28. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
29. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary.
Davis M; Rauh-Hain JA; Andrade C; Boruta DM; Schorge JO; Horowitz NS; May T; del Carmen MG
Gynecol Oncol; 2014 Mar; 132(3):760-6. PubMed ID: 24440832
[TBL] [Abstract][Full Text] [Related]
30. Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma.
Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2018 Jan; 28(1):11-18. PubMed ID: 28930811
[TBL] [Abstract][Full Text] [Related]
31. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
Peres LC; Cushing-Haugen KL; Köbel M; Harris HR; Berchuck A; Rossing MA; Schildkraut JM; Doherty JA
J Natl Cancer Inst; 2019 Jan; 111(1):60-68. PubMed ID: 29718305
[TBL] [Abstract][Full Text] [Related]
32. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
[TBL] [Abstract][Full Text] [Related]
33. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.
Sirichaisutdhikorn D; Suprasert P; Khunamornpong S
Asian Pac J Cancer Prev; 2009; 10(6):1041-5. PubMed ID: 20192580
[TBL] [Abstract][Full Text] [Related]
35. The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study.
Takano M; Sugiyama T; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Kikuchi Y
Int J Gynecol Cancer; 2009 Nov; 19(8):1353-7. PubMed ID: 20009889
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
Crim A; Rowland M; Ruskin R; Dvorak J; Greenwade M; Walter A; Gillen J; Ding K; Moore K; Gunderson C
Gynecol Oncol; 2017 Aug; 146(2):268-272. PubMed ID: 28583323
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors in epithelial ovarian cancer: A population-based study.
Chang LC; Huang CF; Lai MS; Shen LJ; Wu FL; Cheng WF
PLoS One; 2018; 13(3):e0194993. PubMed ID: 29579127
[TBL] [Abstract][Full Text] [Related]
38. Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures.
Tentes AA; Mirelis CG; Markakidis SK; Bekiaridou KA; Bougioukas IG; Xanthoulis AI; Tsalkidou EG; Zafiropoulos GH; Nikas IH
Int J Gynecol Cancer; 2006; 16(2):490-5. PubMed ID: 16681716
[TBL] [Abstract][Full Text] [Related]
39. Comparison of early-stage primary serous fallopian tube carcinomas and equivalent stage serous epithelial ovarian carcinomas.
Horng HC; Lai CR; Chang WH; Wen KC; Chen YJ; Juang CM; Yen MS; Wang PH
Taiwan J Obstet Gynecol; 2014 Dec; 53(4):547-51. PubMed ID: 25510699
[TBL] [Abstract][Full Text] [Related]
40. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
